Kodiak Sciences annual ebitda
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kodiak Sciences EBITDA Growth & History (KOD)
Kodiak Sciences's calculated EBITDA was −$216.1M for fiscal 2025.
View full Kodiak Sciences company overviewKodiak Sciences annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$216.1M | −$47.9M | — |
| 2024 | 2024-12-31 | −$168.1M | $90.9M | — |
| 2023 | 2023-12-31 | −$259.0M | $78.6M | — |
| 2022 | 2022-12-31 | −$337.6M | −$71.5M | — |
| 2021 | 2021-12-31 | −$266.0M | −$130.5M | — |
| 2020 | 2020-12-31 | −$135.5M | −$86.9M | — |
| 2019 | 2019-12-31 | −$48.7M | −$22.8M | — |
| 2018 | 2018-12-31 | −$25.9M | −$912,000 | — |
| 2017 | 2017-12-31 | −$25.0M | −$8.1M | — |
| 2016 | 2016-12-31 | −$16.9M | — | — |
Kodiak Sciences quarterly ebitda
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$62.7M | −$11.8M | — |
| Q1 2026 | 2026-03-31 | −$55.7M | −$1.2M | — |
| Q4 2025 | 2025-12-31 | −$52.9M | −$11.4M | — |
| Q3 2025 | 2025-09-30 | −$57.8M | −$15.8M | — |
| Q2 2025 | 2025-06-30 | −$50.9M | −$7.6M | — |
| Q1 2025 | 2025-03-31 | −$54.5M | −$13.1M | — |
| Q4 2024 | 2024-12-31 | −$41.6M | $17.1M | — |
| Q3 2024 | 2024-09-30 | −$41.9M | $7.5M | — |
| Q2 2024 | 2024-06-30 | −$43.3M | $36.8M | — |
| Q1 2024 | 2024-03-31 | −$41.4M | $29.5M | — |
| Q4 2023 | 2023-12-31 | −$58.6M | $13.9M | — |
| Q3 2023 | 2023-09-30 | −$49.5M | $28.8M | — |
| Q2 2023 | 2023-06-30 | −$80.1M | $11.2M | — |
| Q1 2023 | 2023-03-31 | −$70.8M | $24.7M | — |
| Q4 2022 | 2022-12-31 | −$72.5M | $20.3M | — |
| Q3 2022 | 2022-09-30 | −$78.3M | −$11.0M | — |
| Q2 2022 | 2022-06-30 | −$91.3M | −$35.6M | — |
| Q1 2022 | 2022-03-31 | −$95.5M | −$45.1M | — |
| Q4 2021 | 2021-12-31 | −$92.8M | −$46.1M | — |
| Q3 2021 | 2021-09-30 | −$67.3M | −$30.7M | — |
| Q2 2021 | 2021-06-30 | −$55.7M | −$29.0M | — |
| Q1 2021 | 2021-03-31 | −$50.3M | −$24.7M | — |
| Q4 2020 | 2020-12-31 | −$46.7M | −$30.6M | — |
| Q3 2020 | 2020-09-30 | −$36.6M | −$24.0M | — |
| Q2 2020 | 2020-06-30 | −$26.7M | −$15.0M | — |
| Q1 2020 | 2020-03-31 | −$25.6M | −$17.3M | — |
| Q4 2019 | 2019-12-31 | −$16.1M | −$6.8M | — |
| Q3 2019 | 2019-09-30 | −$12.6M | −$6.3M | — |
| Q2 2019 | 2019-06-30 | −$11.7M | −$6.7M | — |
| Q1 2019 | 2019-03-31 | −$8.3M | −$2.9M | — |
| Q4 2018 | 2018-12-31 | −$9.2M | — | — |
| Q3 2018 | 2018-09-30 | −$6.3M | −$2.4M | — |
| Q2 2018 | 2018-06-30 | −$5.0M | — | — |
| Q1 2018 | 2018-03-31 | −$5.4M | — | — |
| Q3 2017 | 2017-09-30 | −$3.9M | — | — |
Kodiak Sciences ebitda trends
Over the last five fiscal years, Kodiak Sciences's ebitda decreased from −$135.5M to −$216.1M, a change of −$80.5M. The latest reported quarter, Q2 2026, shows −$62.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kodiak Sciences source filings ↗Community posts
Kodiak’s two retinal treatments meet pivotal trial endpoints
Kodiak Sciences ($KOD) reported that Zenkuda and tabirafusp-ted met their primary vision endpoints in the Phase 3 DAYBREAK trial in wet age-related macular degeneration. Both achieved non-inferior vision gains against aflibercept at one yea ...
